SIMCERE PHARMA (HK.2096) to host 2022 R&D Day

HONG KONG,April 7,2022 --SIMCERE PHARMA (HK.2096),an innovation and R&D-driven pharmaceutical company with a mission of "providing today's patients with medicines of the future",will host a virtual R&D Day,onFriday,15 April,2022,at 21:00-23:00 (HKT) / 9:00-11:00 (EST) / 13:00-15:00 (GMT).

SIMCERE PHARMA 2022 R&D DAY AGENDA

The R&D Day will feature presentations from Mr. Ren Jinsheng(Chairman of the Board & CEO),Mr. Zhou Gaobo(CIO),Dr. Tang Renhong(EVP),Dr. Bijoyesh Mookerjee(CMO),Dr. Danny Chen(SVP) and Dr. Kevin Oliver(SVP).

A live question and answer session will follow. To register for the event,please clickhere(https://www.simcere.com/xs2022/).

For further information,please contact:

Jason Bao,The Secretary of the Board

E-mail:ir@simcere.com

About Simcere

Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The company focuses on three therapeutic areas,oncology,central nervous system,and autoimmune diseases,with forward-looking layout of disease areas that may have significant clinical needs in the future,aiming to achieve the mission of "providing today's patients with medicines of the future." Bases on its R&D and commercialization excellence,Simcere is in a leading position for its main products in the Chinese market. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.